首页> 外文期刊>Human antibodies >Novel antiphospholipid antibodies in autoimmune bullous diseases
【24h】

Novel antiphospholipid antibodies in autoimmune bullous diseases

机译:Novel antiphospholipid antibodies in autoimmune bullous diseases

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Pemphigus and bullous pemphigoid are two autoimmune diseases that have similar pathogenesis. Both have a genetic predisposition, which promotes the production of auto antibodies targeted against different components of the epidermal desmosome and hemidesmosome. Antiphospholipid antibodies (aPL) are heterogeneous group of antibodies found in patients with autoimmune diseases and inflammatory conditions and are associated with thrombotic events, OBJECTIVE: We sought to determine the expression profile of eight non classical aPLs in ABD patients. METHODS: A cohort of 266 serum samples of patients with pemphigus, bullous pemphigoid and controls was screened for the presence of eight aPL antibodies, using the Bio-Rad BioPlex~(TM)2200 system. RESULTS: Phosphatidylserine-beta-2-glycoprotein-I (aPS-beta2GPI) and anti prothrombin complex (aPT-PT) serum profiles were significantly more prevalent among ABD patients; 20.7 patients with ABD compared to 5.9 of control patients were positive for aPS-beta2GPI IgM. In addition, aPT-PT IgM was more prevalent among ABD patients (31 vs. 14.8).CONCLUSION: aPL auto antibodies are more prevalent in ABD. Any clinical association should be further determined.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号